Vol. 6, Issue 1, Part A (2024)

Background: (NSTEMI) cases have higher chances of cardiac as well as non-cardiac comorbidities than STEMI patients. The aim of this work was aimed at assessing the CHA2DS2-VASc-HS score’s impact on predicting negative hospital-based consequences among cases having NSTEMI.
Methods: Our prospective cohort study involved 100 cases, both sexes, having NSTEMI present with acute coronary syndrome (ACS)-like symptoms as well as an increased Troponin but no ST-segment elevation abnormalities consistent with STEMI on the electrocardiogram (ECG). The adverse in-hospital outcomes were heart failure, recurrent ischemia, major arrhythmias, cardiogenic shock, and death.
Results: A statistically significant variation was documented between absent as well as present (adverse in-hospital outcomes) regarding CHDA2S2VASC-HS score (P=0.019). The ideal cut off point of CHDA2S2VASC- HS score for Adverse in-hospital outcome’s prediction was found ≥ 4.0 with sensitivity (83.3%), specificity (56.82%), positive predictive value (20.8%), negative predictive value (96.2%) as well as a total accuracy (68.0%). 
Conclusion: CHA2DS2-VASc-HS scores could be utilized while predicting the unfavorable clinical events’ probability, during hospital stay among NSTEMI cases such as: HF, recurrent ischemia, major arrhythmias, cardiogenic shock and death. NSTEMI cases having a CHA2DS2-VASc-HS score equal or above four were associated with exaggerated negative hospital-based consequences.